Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
20.9.2022 15:02:00 EEST | Business Wire | Press release
Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis. This study is an update to a 2020 interim analysis and was announced at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220920005519/en/
The Impella 5.5 with SmartAssist heart pump delivers full cardiac support, allowing the heart to rest and enabling the heart to achieve its natural pumping function without additional support. This heart pump is designed for long-duration support, enables patient mobility and optimizes recovery by using real-time intelligence. (Graphic: Business Wire)
The analysis examined 143 consecutive patients with cardiogenic shock due to myocarditis who received Impella support or Impella plus VA ECMO support, known as ECpella. These patients are included in the J-PVAD registry, a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS). The results demonstrated a 77% survival at 30 days for these patients. A previous analysis of myocarditis patients who only received VA ECMO support found 48% survival at 30 days (Journal of Heart and Lung Transplantation, 2021).
“These findings further demonstrate the potential of increasing native heart recovery in myocarditis patients through the use of Impella, which is an important consideration given the limited number of heart transplants,” said lead investigator Koichi Toda, MD, a cardiovascular surgeon at the department of cardiovascular surgery at Osaka University Graduate School of Medicine.
Myocarditis is the inflammation of the heart muscle often caused by a viral infection. This inflammation may affect the heart’s electrical system and cause the muscle to enlarge, which has the potential to weaken the heart and force it to work harder to circulate blood and oxygen to the rest of the body. Ultimately, this could lead to heart failure.
According to a U.S. Centers for Disease Control and Prevention (CDC) report, rates of myocarditis have increased since the start of the COVID-19 pandemic to approximately 146 cases per 100,000 people, up from <10 cases per 100,000 people. The same report also showed that patients with COVID-19 had close to 16 times the risk for developing myocarditis compared to patients who did not have COVID-19.
“Myocarditis is a growing epidemic in the COVID-19 era. It is exciting to see data from this study demonstrates the potential for Impella support to improve patient outcomes in this very sick patient population,” said Masahiro Ono, MD, a cardiovascular surgeon at Methodist Healthcare in San Antonio, Texas.
In Aug. 2020, the U.S. FDA issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis.
In January 2022, 31-year-old Bobby Goines, a husband, father of three and sales representative from Conway, AR, was diagnosed with myocarditis due to COVID-19 and was in cardiogenic shock. At CHI St. Vincent, Dr. Thurston Bauer implanted Impella 5.5 with SmartAssist to support Bobby’s heart and allow it to rest. After eight days of support, during which Bobby was able to walk around the unit and his condition improved, Impella was weaned and removed. Bobby returned home with normal heart function and is now back to work and enjoying time with his family. You can learn more about Bobby’s heart recovery story here.
ABOUT IMPELLA HEART PUMPS
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD® and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (ABMD) is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005519/en/
Contact information
Media Contact:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com
Investor Contact:
Todd Trapp
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally19.11.2026 23:11:00 EET | Press release
This announcement replaces the release dated November 17, 2026 with the following version: J.P. Morgan Payments was added to the subhead and after the 11th paragraph. Multimedia was also updated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ Visa Agentic Ready Acceptance Partners The updated release reads: VISA EXPANDS AGENTIC READY TO HELP SCALE TRUSTED AI COMMERCE GLOBALLY Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, J.P. Morgan Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem. Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commer
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 18:30:00 EET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 17:24:00 EET | Press release
When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 17:04:00 EET | Press release
North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 16:32:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally required paying to reach them again. Meanwhile, direct web sales have become a major revenue ch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
